One of the shortcomings of a therapy that uses millions of identical antibodies to boost the immune system’s attack on cancer cells is that many patients whose tumours recede in response to the treatm
More: continued here
Blogsphere: TechnoratiFeedsterBloglines
Bookmark: Del.icio.usSpurlFurlSimpyBlinkDigg
RSS feed for comments on this post | TrackBack URI for this post
Best Deal Ads :






